Arcus Begins Differentiating Its HIF-2a Inhibitor Versus Merck’s Welireg

Although from a small Phase I/Ib study, Arcus presents data showing better response rate, disease control and tolerability for casdatifan compared to Merck’s approved renal cell carcinoma drug Welireg.